Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic... Letters 5 patients were considered to have a partial response accord- static EGFR-mutant lung cancers. However, the 19-month me- ing to the Response Evaluation Criteria in Solid Tumors, ver- dian progression-free survival (PFS) in the study was compa- sion 1.1 criteria. Wang and colleagues requested more details rable with the median PFS with osimertinib alone (19 months) on the 5 patients determined to be nonresponders on central in the FLAURA study. We wish to put forth the following dis- review who were classified as responders by investigator cussion points. review. All 5 nonresponders on central review had a median First, they considered that the characteristics of the pa- of 2 lines of therapy that failed. Three patients had intrahe- tients in the current study differed from those in the earlier patic cholangiocarcinoma, 1 patient had extrahepatic study, which enrolled a higher proportion of individuals with cholangiocarcinoma, and the last patient had gallbladder can- preexisting brain metastases (31% vs 19%). However, detailed cer. The median progression-free survival and overall sur- PFS findings in patients with and without brain metastases vival were 19.2 (95% CI, 16.6-21.8) months and 21.5 (95% CI, were not presented from the published data, although we have http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply

JAMA Oncology , Volume 6 (12) – Dec 29, 2020

Loading next page...
 
/lp/american-medical-association/combination-of-osimertinib-and-bevacizumab-as-first-line-treatment-for-1AkPAkpLSb
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.4824
Publisher site
See Article on Publisher Site

Abstract

Letters 5 patients were considered to have a partial response accord- static EGFR-mutant lung cancers. However, the 19-month me- ing to the Response Evaluation Criteria in Solid Tumors, ver- dian progression-free survival (PFS) in the study was compa- sion 1.1 criteria. Wang and colleagues requested more details rable with the median PFS with osimertinib alone (19 months) on the 5 patients determined to be nonresponders on central in the FLAURA study. We wish to put forth the following dis- review who were classified as responders by investigator cussion points. review. All 5 nonresponders on central review had a median First, they considered that the characteristics of the pa- of 2 lines of therapy that failed. Three patients had intrahe- tients in the current study differed from those in the earlier patic cholangiocarcinoma, 1 patient had extrahepatic study, which enrolled a higher proportion of individuals with cholangiocarcinoma, and the last patient had gallbladder can- preexisting brain metastases (31% vs 19%). However, detailed cer. The median progression-free survival and overall sur- PFS findings in patients with and without brain metastases vival were 19.2 (95% CI, 16.6-21.8) months and 21.5 (95% CI, were not presented from the published data, although we have

Journal

JAMA OncologyAmerican Medical Association

Published: Dec 29, 2020

References